Avidity Biosciences Inc (RNA) Company Profile & Statistics

Avidity Biosciences Inc
RNA
(Nasdaq - US)
Open
41.06
-1.12 (-2.65%)
in:usd•As of: Nov 18, 2024 12:48 UTC -5
Open
41.91
High
42.28
Low
39.61

About Avidity Biosciences Inc

CEO

Sarah Boyce

Headquarters

10578 science center drive,suite 125

san diego, ca 92121, united states

Auditor

BDO USA, LLP

Employees

253

Share Holders

Website

www.aviditybiosciences.com

Industry

biotechnology

Sector

health technology

Company Overview

Avidity Biosciences Inc. is a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates(TM). The company's AOC platform design, engineer and develop therapeutics which combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies. Its lead product candidate consist AOC 1001, is designed to treat myotonic dystrophy type 1,and other muscle programs are focused on the treatment of muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and Pompe disease. Avidity Biosciences Inc. is based in SAN DIEGO.

Avidity Biosciences Inc Statistics

Valuation Measures

Market Capitalization ²	4.90B
Enterprise Value	4.53B
Enterprise Value/EBITDA (ttm)	-13.34
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	3.35
Price to Sales (ttm)	497.43
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	100.00%
Operating Margin (ttm)	-2772.45%
Profit Margin (ttm)	-2900.76%
Return on Equity (ttm)	-27.66%
Return on Invested Capital (ttm)	-31.50%
Return on Assets (ttm)	-24.56%

Income Statement

Revenue (ttm)	10.12M
Revenue Per Share (ttm)	0.08
Gross Profit (ttm)	10.12M
EBITDA (ttm)³	-339.56M
Net Income Avi to Common (ttm)	-280.49M
Diluted EPS (ttm)	-2.88

Share Statistics

Beta (5Y Monthly)	0.91
52-Week Change	587.77%
S&P500 52-Week Change	29.66%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	119.31M
Dividend Yield	0.00%
Float ⁴	114.92M
% Held by Insiders	3.68%
% Held by Institutions	N/A

Balance Sheet

Total Cash (mrq)	1.59B
Total Cash Per Share (mrq)	13.31
Total Debt (mrq)	0.00
Total Debt/Equity (mrq)	0.00%
Current Ratio (mrq)	17.76%
Quick Ratio (mrq)	17.76%
Book Value Per Share (mrq)	12.64

Cash Flow

Operating Cash Flow Per Share (ytd)	-1.63
Free Cash Flow (ytd)	-204.15M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Avidity Biosciences Inc

Trade With A Regulated Broker